Vertex's New Drug Launches Fall Short of Expectations, Raising Pressure on Pipeline
Vertex Pharmaceuticals, a leading player in the cystic fibrosis treatment market, reported mixed results in its latest earnings report, with its newest products underperforming Wall Street expectations. The company's overall revenue growth was driven primarily by its flagship cystic fibrosis drug, Trikafta, while recently launched treatments for pain and blood disorders showed slower-than-anticipated uptake.
